Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

(2017) Kevin J. Freise et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin’s Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis

(2016) Aksana K. Jones et al.   AAPS Journal

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis

(2016) Kevin J. Freise et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 2045: Relationship of venetoclax dose and exposure to response in relapsed or refractory chronic lymphocytic leukemia and non-Hodgkin's lymphoma subjects

(2016) Kevin J. Freise et al.   CANCER RESEARCH

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers

(2016) Ahmed Hamed Salem et al.   CLINICAL DRUG INVESTIGATION

Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

(2016) Kevin J. Freise et al.   CLINICAL PHARMACOKINETICS

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy

(2016) Kevin J. Freise et al.   HEMATOLOGICAL ONCOLOGY

Hematologic malignancies: newer strategies to counter the BCL-2 protein

(2016) Abdul Shukkur Ebrahim et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study

(2016) Suresh K. Agarwal et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

(2016) Ahmed Hamed Salem et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

All-Comers versus Enrichment Design Strategy in Phase II Trials

(2011) Sumithra J. Mandrekar et al.   Journal of Thoracic Oncology

Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia

(2008) Meletios Athanasios Dimopoulos et al.   JOURNAL OF CLINICAL ONCOLOGY